News
PBYI
8.77
+0.92%
0.08
Weekly Report: what happened at PBYI last week (0803-0807)?
Weekly Report · 1d ago
Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades
Simply Wall St · 4d ago
Puma Biotechnology Is Maintained at Hold by TD Cowen
Dow Jones · 4d ago
TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6
Benzinga · 4d ago
Puma Biotechnology price target raised to $6 from $5 at TD Cowen
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF) and Puma Biotechnology (PBYI)
TipRanks · 5d ago
Puma Biotechnology sees Q3 revenue $56M-$59M
TipRanks · 5d ago
Puma Biotechnology raises FY26 revenue to $224M-$231M from $222M-$229M
TipRanks · 5d ago
Press Release: Puma Biotechnology Reports Second -3-
Dow Jones · 5d ago
*Puma Biotechnology 2Q EPS 16c >PBYI
Dow Jones · 5d ago
*Puma Biotechnology 2Q Rev $56.5M >PBYI
Dow Jones · 5d ago
*Puma Biotechnology 2Q Net $8.2M >PBYI
Dow Jones · 5d ago
Puma Biotech: Q2 Earnings Snapshot
Barchart · 5d ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 6d ago
Weekly Report: what happened at PBYI last week (0727-0731)?
Weekly Report · 08/03 09:04
Weekly Report: what happened at PBYI last week (0720-0724)?
Weekly Report · 07/27 09:04
Press Release: Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
Dow Jones · 07/23 20:22
Weekly Report: what happened at PBYI last week (0713-0717)?
Weekly Report · 07/20 09:04
Weekly Report: what happened at PBYI last week (0706-0710)?
Weekly Report · 07/13 09:04
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 07/07 21:05
More
Webull provides a variety of real-time PBYI stock news. You can receive the latest news about Puma Biotechnology Inc through multiple platforms. This information may help you make smarter investment decisions.
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.